January 5, 2017 / 11:44 AM / 8 months ago

BRIEF-Genocea announces positive 6-month results from mid-satge trial

Jan 5 (Reuters) - Genocea Biosciences Inc -

* Genocea announces positive 6-month results from gen-003 phase 2b clinical trial

* End of phase 2 meeting with FDA expected in Q1 2017

* Phase 3 launch expected in Q4 2017

* Trial meets statistical significance versus placebo for multiple clinical endpoints through six months

* Gen-003 also consistently demonstrated significant benefits versus placebo across several other clinical endpoints Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below